Eugenia B. Negredo

Eugenia B. Negredo

Vic, CT 08500, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Gender-Specific Determinants of Frailty in Aging People with HIV: Evidence for a Multidimensional Vulnerability Phenotype in Women.

Gender-Specific Determinants of Frailty in Aging People with HIV: Evidence for a Multidimensional Vulnerability Phenotype in Women.

Journal: Viruses

Published: June 09, 2026

Multiparametric Characterization of Telomere Length in T Cells by Flow-FISH.

Multiparametric Characterization of Telomere Length in T Cells by Flow-FISH.

Journal: Current protocols

Published: April 17, 2026

Implementing Semi-Automated Medication Dispensing for People with HIV: A Community-Based Alternative to Traditional Pharmacy Pickups.

Implementing Semi-Automated Medication Dispensing for People with HIV: A Community-Based Alternative to Traditional Pharmacy Pickups.

Journal: Healthcare (Basel, Switzerland)

Published: January 05, 2026

actHIVa Cataluña: Consensus to improve comprehensive care and long-term quality of life for vulnerable people living with HIV in Catalonia.

actHIVa Cataluña: Consensus to improve comprehensive care and long-term quality of life for vulnerable people living with HIV in Catalonia.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: December 15, 2025

Strategies to Minimize Time From HIV Acquisition to ART Initiation: The Barcelona Early-cART Program.

Strategies to Minimize Time From HIV Acquisition to ART Initiation: The Barcelona Early-cART Program.

Journal: Open forum infectious diseases

Published: July 03, 2025

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.

Journal: HIV medicine

Published: June 23, 2025

Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study.

Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study.

Journal: Viruses

Published: May 13, 2025

Short Assessment for People with Human Immunodeficiency Virus (HIV) Aged 50 Years or Older: Essential Tests from Comprehensive Geriatric Assessment.

Short Assessment for People with Human Immunodeficiency Virus (HIV) Aged 50 Years or Older: Essential Tests from Comprehensive Geriatric Assessment.

Journal: Viruses

Published: April 29, 2025

Muscular and plasma markers for early identification of frailty and sarcopenia states in people with HIV.

Muscular and plasma markers for early identification of frailty and sarcopenia states in people with HIV.

Journal: AIDS (London, England)

Published: April 25, 2025

Transforming long-term care for people with HIV: Movimiento AHORA.

Transforming long-term care for people with HIV: Movimiento AHORA.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: April 23, 2025

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)-a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol.

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)-a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol.

Journal: BMJ open

Published: April 11, 2025

48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial.

48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial.

Journal: The Journal of antimicrobial chemotherapy

Published: January 12, 2025

Showing 1-12 of 127

Last Updated: 09/26/2026